{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T14:43:20Z","timestamp":1787755400690,"version":"build-2784847793"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T00:00:00Z","timestamp":1721260800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck & Co.","doi-asserted-by":"publisher","award":["60369"],"award-info":[{"award-number":["60369"]}],"id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Patients with B-cell lymphoma and acute lymphoblastic leukemia (ALL) who receive chimeric antigen receptor T-cell (CAR-T) therapy may experience clinically significant cytomegalovirus infection (CS-CMVi). However, risk factors for CS-CMVi are not well defined. The aims of our study were to identify risk factors for CS-CMVi and the association between CS-CMVi and nonrelapse mortality (NRM) in lymphoma and ALL patients after CAR-T therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a retrospective single-center cohort analysis of CAR-T recipients between January 2018 and February 2021 for treatment of lymphoma and ALL. We collected data on demographics, oncologic history, CAR-T therapy\u2013related complications, and infectious complications within 1 year of therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 230 patients identified, 22 (10%) had CS-CMVi. At 1 year following CAR-T therapy, 75 patients (33%) developed relapsed disease and 95 (41%) died; NRM at 1 year was 37%. On Cox regression analysis, Asian or Middle Eastern race (adjusted hazard ratio [aHR], 13.71 [95% confidence interval {CI}, 5.41\u201334.74]), treatment of cytokine release syndrome\/immune effector cell\u2013associated neurotoxicity syndrome with steroids (aHR, 6.25 [95% CI, 1.82\u201321.47]), lactate dehydrogenase at time of CAR-T therapy (aHR, 1.09 [95% CI, 1.02\u20131.16]), and CMV surveillance (aHR, 6.91 [95% CI, 2.77\u201317.25]) were independently associated with CS-CMVi. CS-CMVi was independently associated with NRM at 1 year after CAR-T therapy (odds ratio, 2.49 [95% CI, 1.29\u20134.82]).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Further studies of immunologic correlatives and clinical trials to determine the efficacy of prophylactic strategies are needed to understand the role of CS-CMVi and post\u2013CAR-T mortality.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ofid\/ofae422","type":"journal-article","created":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T04:14:40Z","timestamp":1721276080000},"source":"Crossref","is-referenced-by-count":26,"title":["Cytomegaloviral Infections in Recipients of Chimeric Antigen Receptor T-Cell Therapy: An Observational Study With Focus on Oncologic Outcomes"],"prefix":"10.1093","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4424-283X","authenticated-orcid":false,"given":"Fareed","family":"Khawaja","sequence":"first","affiliation":[{"name":"Division of Internal Medicine, Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center , Houston, Texas , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7302-8299","authenticated-orcid":false,"given":"Sairah","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Division of Cancer Medicine, Department of Lymphoma\/Myeloma, The University of Texas MD Anderson Cancer Center , Houston, Texas , USA"},{"name":"Division of Cancer Medicine, Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center , Houston, Texas , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1646-813X","authenticated-orcid":false,"given":"Swaminathan P","family":"Iyer","sequence":"additional","affiliation":[{"name":"Division of Cancer Medicine, Department of Lymphoma\/Myeloma, The University of Texas MD Anderson Cancer Center , Houston, Texas , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8730-8929","authenticated-orcid":false,"given":"Joseph","family":"Sassine","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine, Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center , Houston, Texas , USA"},{"name":"Infectious Diseases Section, Department of Medicine, University of Oklahoma Health Sciences Center , Oklahoma City, Oklahoma , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1678-5848","authenticated-orcid":false,"given":"Guy","family":"Handley","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine, Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center , Houston, Texas , USA"},{"name":"Division of Infectious Disease and International Medicine, Department of Medicine, Morsani College of Medicine, University of South Florida , Tampa, Florida , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rishab","family":"Prakash","sequence":"additional","affiliation":[{"name":"Division of Cancer Medicine, Department of Lymphoma\/Myeloma, The University of Texas MD Anderson Cancer Center , Houston, Texas , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy","family":"VanWierren","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine, Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center , Houston, Texas , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Jackson","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine, Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center , Houston, Texas , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Zubovskaia","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine, Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center , Houston, Texas , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8984-3420","authenticated-orcid":false,"given":"Jeremy","family":"Ramdial","sequence":"additional","affiliation":[{"name":"Division of Cancer Medicine, Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center , Houston, Texas , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Rondon","sequence":"additional","affiliation":[{"name":"Division of Cancer Medicine, Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center , Houston, Texas , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krina K","family":"Patel","sequence":"additional","affiliation":[{"name":"Division of Cancer Medicine, Department of Lymphoma\/Myeloma, The University of Texas MD Anderson Cancer Center , Houston, Texas , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7513-6522","authenticated-orcid":false,"given":"Amy","family":"Spallone","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine, Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center , Houston, Texas , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4543-6177","authenticated-orcid":false,"given":"Ella J","family":"Ariza-Heredia","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine, Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center , Houston, Texas , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7028-4860","authenticated-orcid":false,"given":"Victor","family":"Mulanovich","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine, Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center , Houston, Texas , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Angelidakis","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine, Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center , Houston, Texas , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Jiang","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine, Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center , Houston, Texas , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0277-3088","authenticated-orcid":false,"given":"Roy F","family":"Chemaly","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine, Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center , Houston, Texas , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,7,18]]},"reference":[{"key":"2024082915051543500_ofae422-B1","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1007\/s10147-023-02334-w","article-title":"Safety and efficacy of tisagenlecleucel in patients with relapsed or refractory B-cell lymphoma: the first real-world evidence in Japan","volume":"28","author":"Goto","year":"2023","journal-title":"Int J Clin Oncol"},{"key":"2024082915051543500_ofae422-B2","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"2024082915051543500_ofae422-B3","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/hon.3153","article-title":"CAR T-cell therapy in large B cell lymphoma","volume":"41","author":"Boardman","year":"2023","journal-title":"Hematol Oncol"},{"key":"2024082915051543500_ofae422-B4","doi-asserted-by":"crossref","first-page":"e1006","DOI":"10.1016\/S2352-3026(23)00307-1","article-title":"CD19-directed CAR T cells as first salvage therapy for large B-cell lymphoma: towards a rational approach","volume":"10","author":"Dreger","year":"2023","journal-title":"Lancet Haematol"},{"key":"2024082915051543500_ofae422-B5","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1007\/s11899-018-0470-x","article-title":"CAR-T cell therapy for acute lymphoblastic leukemia: transforming the treatment of relapsed and refractory disease","volume":"13","author":"Pehlivan","year":"2018","journal-title":"Curr Hematol Malig Rep"},{"key":"2024082915051543500_ofae422-B6","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1002\/ajh.26301","article-title":"Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed\/refractory aggressive B-cell lymphomas: observations from the JULIET, ZUMA-1, and TRANSCEND trials","volume":"96","author":"Westin","year":"2021","journal-title":"Am J Hematol"},{"key":"2024082915051543500_ofae422-B7","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"2024082915051543500_ofae422-B8","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1097\/QCO.0000000000000679","article-title":"Infections after anti-CD19 chimeric antigen receptor T-cell therapy for hematologic malignancies: timeline, prevention, and uncertainties","volume":"33","author":"Haidar","year":"2020","journal-title":"Curr Opin Infect Dis"},{"issue":"Suppl 1","key":"2024082915051543500_ofae422-B9","doi-asserted-by":"crossref","first-page":"e14157","DOI":"10.1111\/tid.14157","article-title":"Infections after chimeric antigen receptor (CAR)-T-cell therapy for hematologic malignancies","volume":"25","author":"Kampouri","year":"2023","journal-title":"Transpl Infect Dis"},{"key":"2024082915051543500_ofae422-B10","doi-asserted-by":"crossref","first-page":"6589","DOI":"10.1182\/bloodadvances.2023010624","article-title":"Nonrelapse mortality after CAR T-cell therapy for large B-cell lymphoma: a LYSA study from the DESCAR-T registry","volume":"7","author":"Lemoine","year":"2023","journal-title":"Blood Adv"},{"key":"2024082915051543500_ofae422-B11","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1007\/s00277-023-05131-7","article-title":"Infectious complications following CAR-t cell therapy for B cell non-Hodgkin lymphoma: a single-center experience and review of the literature","volume":"102","author":"Mercadal","year":"2023","journal-title":"Ann Hematol"},{"key":"2024082915051543500_ofae422-B12","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1093\/cid\/ciab298","article-title":"Refractory and resistant cytomegalovirus after hematopoietic cell transplant in the letermovir primary prophylaxis era","volume":"73","author":"Sassine","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2024082915051543500_ofae422-B13","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1093\/cid\/ciu364","article-title":"Donor cytomegalovirus status influences the outcome of allogeneic stem cell transplant: a study by the European Group for Blood and Marrow Transplantation","volume":"59","author":"Ljungman","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2024082915051543500_ofae422-B14","doi-asserted-by":"crossref","first-page":"e13289","DOI":"10.1111\/tid.13289","article-title":"Microbiologically documented infections after adult allogeneic hematopoietic cell transplantation: a 5-year analysis within the Swiss Transplant Cohort Study","volume":"22","author":"Vu","year":"2020","journal-title":"Transpl Infect Dis"},{"key":"2024082915051543500_ofae422-B15","doi-asserted-by":"crossref","first-page":"e13483","DOI":"10.1111\/tid.13483","article-title":"Epidemiology, risk factors, and outcomes associated with cytomegalovirus in adult kidney transplant recipients: a systematic literature review of real-world evidence","volume":"23","author":"Raval","year":"2021","journal-title":"Transpl Infect Dis"},{"key":"2024082915051543500_ofae422-B16","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jcv.2017.08.006","article-title":"Cytomegalovirus reactivation in lymphoma and myeloma patients undergoing autologous peripheral blood stem cell transplantation","volume":"95","author":"Massoud","year":"2017","journal-title":"J Clin Virol"},{"key":"2024082915051543500_ofae422-B17","doi-asserted-by":"crossref","first-page":"182","DOI":"10.3109\/10428194.2013.798867","article-title":"Cytomegalovirus infection and end-organ disease in Asian patients with lymphoma receiving chemotherapy","volume":"55","author":"Tay","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"2024082915051543500_ofae422-B18","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.3109\/10428194.2013.825372","article-title":"Prevalence and patterns of cytomegalovirus DNAemia in adult patients with acute lymphoblastic leukemia on chemotherapy","volume":"55","author":"Gulia","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"2024082915051543500_ofae422-B19","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1186\/s12885-022-10008-5","article-title":"Cytomegalovirus infection in patients with malignant lymphomas who have not received hematopoietic stem cell transplantation","volume":"22","author":"Sato","year":"2022","journal-title":"BMC Cancer"},{"key":"2024082915051543500_ofae422-B20","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3816\/CLM.2006.n.016","article-title":"Cytomegalovirus infection in patients with lymphoma: an important cause of morbidity and mortality","volume":"6","author":"Torres","year":"2006","journal-title":"Clin Lymphoma Myeloma"},{"key":"2024082915051543500_ofae422-B21","doi-asserted-by":"crossref","first-page":"851.e1","DOI":"10.1016\/j.jtct.2022.09.007","article-title":"Impact of cytomegalovirus replication in patients with aggressive B cell lymphoma treated with chimeric antigen receptor T cell therapy","volume":"28","author":"M\u00e1rquez-Algaba","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"2024082915051543500_ofae422-B22","doi-asserted-by":"crossref","first-page":"615","DOI":"10.3324\/haematol.2022.281719","article-title":"Cytomegalovirus reactivation after CD19 CAR T-cell therapy is clinically significant","volume":"108","author":"Chen","year":"2023","journal-title":"Haematologica"},{"key":"2024082915051543500_ofae422-B23","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1093\/cid\/ciad708","article-title":"CMV reactivation and CMV-specific cell-mediated immunity after chimeric antigen receptor T-cell therapy","volume":"78","author":"Kampouri","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2024082915051543500_ofae422-B24","doi-asserted-by":"crossref","first-page":"6785","DOI":"10.1182\/bloodadvances.2023010653","article-title":"A phase 1 study of prophylactic anakinra to mitigate ICANS in patients with large B-cell lymphoma","volume":"7","author":"Strati","year":"2023","journal-title":"Blood Adv"},{"key":"2024082915051543500_ofae422-B25","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1086\/339329","article-title":"Definitions of cytomegalovirus infection and disease in transplant recipients","volume":"34","author":"Ljungman","year":"2002","journal-title":"Clin Infect Dis"},{"key":"2024082915051543500_ofae422-B26","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"2024082915051543500_ofae422-B27","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/mpr.124","article-title":"Graphing survival curve estimates for time-dependent covariates","volume":"11","author":"Schultz","year":"2002","journal-title":"Int J Methods Psychiatr Res"},{"key":"2024082915051543500_ofae422-B28","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.cmi.2022.07.001","article-title":"Cytomegalovirus infection in transplant recipients: newly approved additions to our armamentarium","volume":"29","author":"Khawaja","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"2024082915051543500_ofae422-B29","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1016\/j.bbmt.2018.05.001","article-title":"Deleterious effect of steroids on cytomegalovirus infection rate after allogeneic stem cell transplantation depends on pretransplant cytomegalovirus serostatus of donors and recipients","volume":"24","author":"Su\u00e1rez-Lled\u00f3","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"2024082915051543500_ofae422-B30","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1182\/blood.2019002729","article-title":"International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI","volume":"135","author":"Ruppert","year":"2020","journal-title":"Blood"},{"key":"2024082915051543500_ofae422-B31","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jtct.2020.10.022","article-title":"The international prognostic Index is associated with outcomes in diffuse large B cell lymphoma after chimeric antigen receptor T cell therapy","volume":"27","author":"Garcia-Recio","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"2024082915051543500_ofae422-B32","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1182\/hematology.2023000436","article-title":"CAR T-cell therapy in aggressive lymphomas\u2014identifying prognostic and predictive markers","volume":"2023","author":"Mussetti","year":"2023","journal-title":"Hematology"},{"issue":"Suppl 1","key":"2024082915051543500_ofae422-B33","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1093\/infdis\/jiz454","article-title":"Cytomegalovirus infection in solid organ and hematopoietic cell transplantation: state of the evidence","volume":"221","author":"Haidar","year":"2020","journal-title":"J Infect Dis"},{"key":"2024082915051543500_ofae422-B34","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1111\/j.1600-6143.2006.01413.x","article-title":"Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients","volume":"6","author":"Khoury","year":"2006","journal-title":"Am J Transplant"},{"key":"2024082915051543500_ofae422-B35","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/TP.0b013e318238dab3","article-title":"Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial","volume":"93","author":"Witzke","year":"2012","journal-title":"Transplantation"},{"key":"2024082915051543500_ofae422-B36","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N Engl J Med"},{"key":"2024082915051543500_ofae422-B37","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1182\/blood.V93.5.1781","article-title":"Successful modification of a pp65 antigenemia-based early treatment strategy for prevention of cytomegalovirus disease in allogeneic marrow transplant recipients","volume":"93","author":"Boeckh","year":"1999","journal-title":"Blood"},{"key":"2024082915051543500_ofae422-B38","first-page":"2062","article-title":"How I prevent viral reactivation in high-risk patients","volume":"141","author":"Dadwal","year":"2023","journal-title":"Blood"},{"key":"2024082915051543500_ofae422-B39","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1182\/bloodadvances.2019000814","article-title":"Heterogeneous impact of cytomegalovirus reactivation on nonrelapse mortality in hematopoietic stem cell transplantation","volume":"4","author":"Kaito","year":"2020","journal-title":"Blood Adv"},{"key":"2024082915051543500_ofae422-B40","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1111\/j.1600-6143.2009.02824.x","article-title":"The \u2018indirect\u2019 effects of cytomegalovirus infection","volume":"9","author":"Freeman","year":"2009","journal-title":"Am J Transplant"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofae422\/58584071\/ofae422.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/11\/8\/ofae422\/58874872\/ofae422.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/11\/8\/ofae422\/58874872\/ofae422.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T16:37:12Z","timestamp":1724949432000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofae422\/7716186"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,18]]},"references-count":40,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,7,30]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofae422","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,8]]},"published":{"date-parts":[[2024,7,18]]},"article-number":"ofae422"}}